Tirzepatide vs Semaglutide: The 2026 Head-to-Head Comparison
SURMOUNT-5 settled the efficacy question. Tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide at 72 weeks — a 47% greater relative reduction. But efficacy isn't the only factor. Here's the full comparison: weight loss, side effects, dose ladders, current 2026 prices, and who should pick which.
If your priority is maximum weight loss, tirzepatide (Zepbound / Mounjaro) is the clear choice — SURMOUNT-5 confirmed it head-to-head. If your priority is cardiovascular risk reduction, established long-term safety data, or an oral option, semaglutide (Wegovy / Ozempic / Rybelsus) has the deeper evidence base. Both carry the same boxed warning, both require titration, both have similar GI side effects. Through manufacturer direct programs, monthly cost is now within $50–$100 of each other.
SURMOUNT-5: The Direct Comparison
Until 2025, tirzepatide and semaglutide had only been compared indirectly — by lining up the results of separate trials with similar designs. SURMOUNT-5 changed that. The Phase 3b trial randomized 751 adults with obesity (without type 2 diabetes) to maximum tolerated doses of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) for 72 weeks. Results were published in the New England Journal of Medicine in May 2025.
The result was unambiguous on the primary endpoint:
| SURMOUNT-5 Endpoint (72 wks) | Tirzepatide | Semaglutide | Difference |
|---|---|---|---|
| Mean weight loss | −20.2% | −13.7% | 47% greater (relative) |
| Mean weight loss (kg) | −22.8 kg | −15.0 kg | −7.9 kg |
| Achieved ≥25% weight loss | 31.6% | 16.1% | ~2× higher |
| Waist circumference change | −18.4 cm | −13.0 cm | −5.4 cm |
| BMI change | −8.0 kg/m² | −5.3 kg/m² | −2.7 kg/m² |
| GI-related discontinuation | 2.7% | 5.6% | ~½ as many stopped |
Tirzepatide also outperformed semaglutide on every key secondary endpoint that was measured: systolic and diastolic blood pressure, HbA1c, fasting insulin, triglycerides, and HDL cholesterol. Serious adverse events occurred at a similar low rate (4.8% vs 3.5%).
SURMOUNT-5 was an open-label trial funded by Eli Lilly, which manufactures tirzepatide. Both factors warrant transparency. Open-label trials can introduce bias because participants and investigators know which drug is being administered, and the sponsoring manufacturer naturally has an interest in the outcome. That said: the trial was published in NEJM after peer review, the 6.5-percentage-point gap is well outside the range of noise for a trial this size, and a real-world Truveta retrospective study of 6-month outcomes in U.S. clinical practice found similar tirzepatide superiority. The result is robust.
What Each Drug Is
Both are weekly subcutaneous injections that activate the body's incretin system to suppress appetite, slow gastric emptying, and improve glucose handling. The mechanisms differ in one important way:
| Tirzepatide | Semaglutide | |
|---|---|---|
| Mechanism | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist (mono) |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Brand for obesity | Zepbound (FDA approved 11/2023) | Wegovy (FDA approved 6/2021) |
| Brand for T2D | Mounjaro (FDA approved 5/2022) | Ozempic (FDA approved 12/2017) |
| Oral formulation | None approved | Rybelsus (T2D), oral Wegovy (obesity, approved 12/2025) |
| Other approved indications | Obstructive sleep apnea + obesity (12/2024) | Cardiovascular risk reduction in adults with obesity + CVD; MASH (2025) |
| Dosing | Once weekly, subcutaneous | Once weekly injection or once daily oral |
| Half-life | ~5 days | ~7 days |
The mechanistic difference matters. Tirzepatide activates two incretin receptors instead of one, which is the most plausible biological explanation for the consistent efficacy edge across SURMOUNT trials. The clinical relevance of this edge varies by patient.
Dose Ladders
Both drugs require gradual dose escalation to manage gastrointestinal side effects. Most prescribers escalate every 4 weeks, holding at a tolerable dose if escalation produces too much nausea or vomiting.
| Week | Zepbound (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| 1–4 | 2.5 mg | 0.25 mg |
| 5–8 | 5 mg | 0.5 mg |
| 9–12 | 7.5 mg | 1.0 mg |
| 13–16 | 10 mg | 1.7 mg |
| 17–20 | 12.5 mg | 2.4 mg (target) |
| 21+ | 15 mg (target) | 2.4 mg or 7.2 mg HD* |
*Wegovy HD 7.2 mg dose was added in 2025 for patients who need higher exposure. Tirzepatide doses can be held at 5, 10, or 15 mg as maintenance depending on tolerability and response.
Both drugs allow doses to be held or stepped down if side effects are intolerable. SURMOUNT-5 found that fewer tirzepatide patients had to hold or stop their dose due to gastrointestinal side effects despite being on a higher overall mass dose — a counterintuitive finding that underscores how individual response varies.
Side Effects: What to Actually Expect
The side effect profiles are similar in kind but differ slightly in degree. Both drugs share a class effect of gastrointestinal symptoms driven by slowed gastric emptying.
| Side Effect | Tirzepatide | Semaglutide |
|---|---|---|
| Nausea | Most common; usually peaks during titration | Most common; usually peaks during titration |
| Vomiting | Common | Common |
| Diarrhea | Common | Common |
| Constipation | Common | Common |
| Abdominal pain | Common | Common |
| Fatigue / decreased appetite | Common (intentional effect) | Common (intentional effect) |
| Pancreatitis | Rare; warning in label | Rare; warning in label |
| Gallbladder events | Uncommon; warning in label | Uncommon; warning in label |
| Hypoglycemia | Risk with insulin/sulfonylurea co-use | Risk with insulin/sulfonylurea co-use |
| Boxed warning | Thyroid C-cell tumors / MTC / MEN 2 | Thyroid C-cell tumors / MTC / MEN 2 |
The most clinically meaningful side effect difference from SURMOUNT-5: discontinuation due to GI symptoms was 2.7% for tirzepatide vs 5.6% for semaglutide. Translation: in a head-to-head, fewer people had to stop tirzepatide because they couldn't tolerate it.
The boxed warning is identical for both drugs — and applies categorically to anyone with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Detailed coverage of what those warnings mean and who is contraindicated is available in our GLP-1 boxed warning explainer.
Cost Comparison: April 2026 Prices
One of the biggest changes in the past 12 months has been the collapse of the price premium that previously separated these drugs from compounded alternatives. Both manufacturers have aggressively cut self-pay prices.
| Channel | Zepbound (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Manufacturer direct, self-pay | $299–$449/mo (LillyDirect vials) | $199–$349/mo (NovoCare); $399 for HD 7.2 mg |
| Oral form, self-pay | N/A | $149–$299/mo (oral Wegovy via NovoCare) |
| Commercial insurance + savings card | As low as $25/mo | As low as $25/mo |
| Retail (Costco/Walmart cash) | ~$499/mo (Walmart partnership) | ~$499/mo (Costco) |
| List price, no discounts | ~$1,060/mo | ~$1,349/mo |
| Compounded alternative* | $150–$399/mo via licensed telehealth | $99–$269/mo via licensed telehealth |
*Compounded versions are not FDA-approved. Availability and legal status have shifted as the FDA-declared shortages of both drugs ended. Quality and licensing of the prescribing telehealth platform matter.
The headline: through manufacturer direct programs, the monthly cost difference between brand-name Zepbound and brand-name Wegovy is now in the $50–$100 range — small enough that it should rarely be the deciding factor between the two drugs for someone paying cash.
Real-World Evidence: Does the Trial Result Hold Up?
Trial efficacy and real-world effectiveness are not the same thing. Real-world adherence is lower, dose escalation is more conservative, and patient populations are broader. A 2025 retrospective cohort study of U.S. electronic health record data (Truveta) examined adults with obesity (without diabetes) who initiated either tirzepatide or semaglutide between December 2023 and June 2024 and adhered to treatment for 6 months.
The real-world finding: tirzepatide produced significantly greater percentage weight reduction at 6 months than semaglutide, with similar improvements in cardiometabolic parameters. Patients on tirzepatide were also more likely to achieve at least 5%, 10%, and 15% weight loss thresholds. The magnitude of the gap was smaller than in SURMOUNT-5 — partly because of the shorter follow-up — but the direction was the same.
Translation: the head-to-head finding in SURMOUNT-5 holds in messy, real-world American clinical practice. It is not just a controlled-trial artifact.
Where Semaglutide Has the Edge
Tirzepatide wins on raw weight loss. Semaglutide wins on a few other dimensions that matter to specific patient populations:
Cardiovascular outcomes data
Semaglutide has substantially deeper cardiovascular outcomes evidence. The SUSTAIN-6 (2016), SELECT (2023), and SOUL (2025) trials together establish that semaglutide reduces major adverse cardiovascular events in patients with established cardiovascular disease. Wegovy is FDA-approved specifically for cardiovascular risk reduction in adults with obesity and known cardiovascular disease. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is still pending readout — expected within the next year or two.
Available oral formulation
Semaglutide is available as a daily pill in two forms: Rybelsus for type 2 diabetes and oral Wegovy for chronic weight management (FDA approved December 2025). For patients who can't or won't inject, this is decisive. There is currently no oral tirzepatide.
MASH approval
Semaglutide received FDA approval for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) in 2025 — the first GLP-1 with that indication.
Longer real-world track record
Semaglutide has been in widespread clinical use since 2017 (Ozempic) and 2021 (Wegovy). Tirzepatide is newer (2022 / 2023). For patients who place weight on years of post-marketing safety surveillance, semaglutide has a substantially longer track record.
Where Tirzepatide Has the Edge
Greater mean weight loss
SURMOUNT-5 settled this: 20.2% vs 13.7%, a 47% relative advantage. For patients whose primary goal is the largest possible weight loss, tirzepatide is the data-supported choice.
Lower GI discontinuation in head-to-head
Despite a higher mass dose, fewer SURMOUNT-5 participants stopped tirzepatide due to gastrointestinal side effects (2.7% vs 5.6%). This suggests better real-world tolerability for many patients, though individual response varies widely.
Approved for obstructive sleep apnea
Tirzepatide is FDA-approved (December 2024) for moderate-to-severe OSA in adults with obesity. Wegovy is not. For patients whose insurance approval depends on a sleep apnea diagnosis, this matters.
Slightly cheaper through manufacturer direct
LillyDirect Zepbound starts at $299/mo for the 2.5 mg starting dose. NovoCare Wegovy starts at $199/mo for new self-pay patients on the lowest doses for the first two months, then steps to $349/mo. Across maintenance dosing the difference largely evens out, but at the entry point tirzepatide is currently the slightly lower-priced brand.
Who Should Pick Which: A Practical Framework
The honest answer to "which is better" is "it depends on your priorities." Here's the framework most experienced obesity medicine prescribers use:
| If your priority is... | Strong default | Why |
|---|---|---|
| Maximum weight loss | Tirzepatide | SURMOUNT-5 head-to-head |
| Cardiovascular risk reduction | Semaglutide | SELECT, SUSTAIN-6, SOUL outcomes data |
| Oral pill option | Semaglutide | Rybelsus / oral Wegovy approved |
| OSA + obesity (insurance) | Tirzepatide | Only one with that indication |
| MASH + obesity | Semaglutide | Only one with that indication |
| Longest safety track record | Semaglutide | In market since 2017 |
| Already had nausea on semaglutide | Tirzepatide | Lower GI discontinuation in SURMOUNT-5 |
| Lowest entry-month cash price | Semaglutide (oral) | $149/mo via NovoCare for oral Wegovy |
The Switching Question
A common question: "I'm on semaglutide and lost X pounds. Should I switch to tirzepatide for more?" Or the reverse: "I lost weight on tirzepatide. Can I switch to semaglutide for maintenance?"
The clinical answer to both depends on individual response, side effect tolerance, and prescriber judgment — but a couple of evidence-based points are worth knowing:
- Switching from semaglutide to tirzepatide for more weight loss is reasonable and increasingly common. SURMOUNT-5 data supports the rationale. Most prescribers titrate the new drug from a low starting dose, even after established tolerance to the old one.
- Switching from tirzepatide to semaglutide for maintenance is more controversial. Real-world data from EHR studies suggests that patients who succeeded on tirzepatide and switched to semaglutide for maintenance tended to lose ground — likely regaining some weight. If maintenance is the goal, staying on the same molecule (at a maintenance rather than escalation dose) is generally preferred.
- STEP 4 established that discontinuing semaglutide leads to substantial weight regain (roughly two-thirds of weight lost regained by week 68 after stopping). The same chronic-disease principle applies to tirzepatide. Both are long-term treatments for a chronic condition.
Accessing Either Through Telehealth
The fastest path to either medication for most patients is a licensed telehealth platform that handles consultation, prescription, and pharmacy fulfillment as a bundled service. Brand-name access through LillyDirect or NovoCare requires a prescription from any U.S.-licensed clinician and has the lowest cash-pay pricing for the FDA-approved formulations. Compounded versions remain available through some platforms, though the regulatory landscape has tightened since the FDA-declared shortages of both drugs ended.
Comprehensive GLP-1 weight loss program with full medical intake, prescription, and ongoing clinical oversight. Both semaglutide and tirzepatide programs available.
CPA: $500
Compounded semaglutide and tirzepatide programs with full medical consultation and ongoing provider support.
CPA: $350
Direct care platform that prescribes FDA-approved brand-name GLP-1 medications. Book a consultation with a licensed clinician for either Wegovy or Zepbound.
CPA: $175
Frequently Asked Questions
Is tirzepatide just a "stronger" version of semaglutide?
No. They're distinct molecules with different mechanisms. Tirzepatide activates both GIP and GLP-1 receptors; semaglutide activates only the GLP-1 receptor. The dual mechanism is the most plausible explanation for tirzepatide's efficacy advantage, but it's not "the same drug at a higher dose."
Can I take both at the same time?
No. There are no studies of combined use, the side effect risk would be additive, and no professional society recommends it. Patients taking both simultaneously is not standard practice and is generally inadvisable.
Why did SURMOUNT-5 not test the highest-dose semaglutide (7.2 mg HD)?
The Wegovy HD 7.2 mg dose was approved later than the trial design was finalized. SURMOUNT-5 used the maximum approved Wegovy dose at the time the trial was conducted — 2.4 mg. A future head-to-head against the higher-dose version would be informative; none is currently public.
Does insurance cover both?
Coverage varies dramatically by plan. Many commercial plans cover one but not the other, often based on formulary negotiations rather than clinical criteria. If your plan covers one and not the other, that often becomes the deciding factor regardless of clinical preference. Both manufacturers offer $25/month savings cards for commercially insured patients meeting eligibility criteria.
How long do I have to stay on either?
Both are designed for chronic, long-term use. STEP 4 demonstrated that discontinuing semaglutide leads to substantial weight regain (~⅔ of weight lost), and the same is expected of tirzepatide. Obesity is now treated as a chronic relapsing condition, not a temporary problem solved with a temporary medication.
What if I'm contraindicated for both?
The contraindications are the same: personal or family history of medullary thyroid carcinoma, MEN 2, or known hypersensitivity to either drug. If you fall into any of those categories, neither drug is an option. For details, see our GLP-1 boxed warning explainer.
Tirzepatide produces more weight loss than semaglutide — that question is settled by SURMOUNT-5. But "more weight loss" isn't always the right priority. Semaglutide has stronger cardiovascular outcomes data, an oral option, and a longer real-world safety track record. Cost is now close enough through manufacturer direct programs that it shouldn't drive the decision. The right choice is the one whose tradeoffs match your actual priorities.
Sources & References
- Aronne LJ, et al. Tirzepatide vs Semaglutide for Obesity Treatment: SURMOUNT-5. N Engl J Med. 2025. doi:10.1056/NEJMoa2416394. NCT05822830.
- Eli Lilly. Zepbound showed superior weight loss over Wegovy in complete SURMOUNT-5 results published in NEJM. Press release, May 11, 2025. prnewswire.com
- American College of Cardiology. SURMOUNT-5: Greater Loss of Weight, Waist Circumference With Tirzepatide Than Semaglutide. acc.org
- Truveta retrospective cohort study. Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: 6-month results. 2025. PMC12924827
- FDA. Wegovy (semaglutide) Prescribing Information.
- FDA. Zepbound (tirzepatide) Prescribing Information.
- FDA. Mounjaro (tirzepatide) Prescribing Information.
- FDA. Ozempic (semaglutide) Prescribing Information.
- NovoCare. Wegovy savings offer and self-pay pricing. novocare.com
- LillyDirect. Zepbound Self Pay Journey Program pricing. zepbound.lilly.com
- Eli Lilly. Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients. December 1, 2025.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). N Engl J Med. 2023.
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016.
Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, sourcing standards, or comparison data. This article is informational only and does not constitute medical advice. The choice between any two medications is properly made between you and a licensed clinician.